Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report

EML4-ALK rearranged malignant pleural mesothelioma (MPM) is rare and its responses to anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and lorlatinib, remain unexplored. In this case report, we describe a patient with EML4-ALK-rearranged stage IIIB MPM who was administered with alect...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jia, Zhang, Baoshi, Yao, Fangfang, Fu, Yan, Chen, Dianjun, Li, Donghui, Du, Nan, Lizaso, Analyn, Song, Jinlei, Zhang, Lu, Li, Xiaosong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328355/
https://www.ncbi.nlm.nih.gov/pubmed/32600123
http://dx.doi.org/10.1177/1753466620935770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328355/
https://www.ncbi.nlm.nih.gov/pubmed/32600123
http://dx.doi.org/10.1177/1753466620935770

Ejemplares similares